Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

Conavi Medical to Participate in the MedInvest MedTech, AI & Digital Health Conference

Dec 10, 2024 - financialpost.com
Conavi Medical Corp., a company specializing in imaging technologies for cardiovascular procedures, announced that its CEO, Thomas Looby, will present at the MedInvest MedTech, AI & Digital Health Conference on December 11, 2024, in New York City. This marks the first time Conavi is presenting at an investor event as a public company. The presentation will be available via live webcast and archived on the company's website. Conavi's Novasight Hybrid™ System, which combines intravascular ultrasound and optical coherence tomography for coronary artery imaging, has received regulatory approvals in the U.S., Canada, China, and Japan.

The news release includes forward-looking statements about Conavi's future growth and commercialization plans, highlighting potential risks and uncertainties. The company emphasizes that actual results may differ from these projections due to various factors, including the ability to retain key personnel and execute business strategies. Conavi disclaims any obligation to update these statements, advising investors to consider these risks carefully.

Key takeaways:

  • Conavi Medical Corp. will present at the MedInvest MedTech, AI & Digital Health Conference on December 11, 2024, marking its first investor event as a public company.
  • The company's CEO, Thomas Looby, will provide a business update during a live webcast presentation at 3:35 p.m. ET in New York City.
  • Conavi Medical focuses on imaging technologies for minimally invasive cardiovascular procedures, with its Novasight Hybrid™ System combining intravascular ultrasound and optical coherence tomography.
  • The Novasight Hybrid System has received regulatory approvals from the U.S. FDA, Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare.
View Full Article

Comments (0)

Be the first to comment!